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Purpose: It is a challenge to control oxygen saturation (SpO
2
) in patients with exacerbations 
of COPD during admission. We tested a newly developed closed-loop system, O2matic®, 
and its ability to keep SpO
2
 within a specified interval compared with manual control by 
nursing staff.
Patients and methods: We conducted a crossover trial with patients admitted with an exac-
erbation of COPD and hypoxemia (SpO
2
 #88% on room air). Patients were monitored with 
continuous measurement of SpO
2
. In random order, they had 4 hours with manually controlled 
oxygen and 4 hours with oxygen delivery controlled by O2matic. Primary outcome was time 
within a prespecified SpO
2
 target interval. Secondary outcomes were time with SpO
2
 ,85%, 
time with SpO
2
 below target but not ,85%, and time with SpO
2
 above target.
Results: Twenty patients were randomized and 19 completed the study. Mean age was 72.4 years 
and mean FEV
1
 was 0.72 L (33% of predicted). Patients with O2matic-controlled treatment 
were within the SpO
2
 target interval in 85.1% of the time vs 46.6% with manually controlled 
treatment (P,0.001). Time with SpO
2
 ,85% was 1.3% with O2matic and 17.9% with manual 
control (P=0.01). Time with SpO
2
 below target but not ,85% was 9.0% with O2matic and 
25.0% with manual control (P=0.002). Time with SpO
2
 above target was not significantly 
different between treatments (4.6% vs 10.5%, P=0.2). Patients expressed high confidence and 
a sense of safety with automatic oxygen delivery.
Conclusion: O2matic was able to effectively control SpO
2
 for patients admitted with an 
exacerbation of COPD. O2matic was significantly better than manual control to maintain SpO
2
 
within target interval and to reduce time with unintended hypoxemia.
Keywords: oxygen therapy, oxygen saturation, hypoxia, hyperoxia, closed-loop
Introduction
Treatment with oxygen supplementation is a central part of the treatment of exac-
erbations of COPD, as many patients during a hospital admission will have acute 
hypoxemic respiratory failure or worsening of chronic respiratory failure. The reason 
for hypoxemia is mainly deterioration in the ventilation–perfusion mismatch, whereas 
hypercapnia does not occur as long as alveolar ventilation is maintained. There is 
general consensus that oxygen supplementation should be controlled to ensure an 
oxygen saturation (SpO
2
) of 88%–92% for most patients. This is recommended by 
the Global Initiative for Chronic Obstructive Lung Disease and in guidelines for 
treatment of acute hypoxemic respiratory failure.1,2 The evidence, however, for this 
recommendation is sparse due to lack of controlled studies of different levels of 
oxygenation in patients with COPD. One study in a prehospital setting found that 
controlled oxygen, aiming at an SpO
2
 of 88%–92%, compared with liberal oxygen 
dosing of 8–10 L/minute reduced mortality in the COPD population by 78%.3 
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Furthermore, patients who received titrated oxygen were 
significantly less likely to develop respiratory acidosis due 
to acute hypercapnia. In a retrospective study of 680 patients 
presenting with an exacerbation of COPD, the risk of 
serious adverse outcome was increased for both patients 
admitted with an SpO
2
 ,88% and for patients with an 
SpO
2
 .96%.4 Control of SpO
2
 during admission is a 
time-consuming task for the nursing staff, and it has been 
suggested that closed-loop control of oxygenation could 
reduce the burden of the nursing staff and increase patient 
safety by better control of SpO
2
. In a controlled study with 
a closed-loop system, FreeO2® (OxyNov Inc., Québec, 
Canada), time within SpO
2
 target interval was increased 
from 51% to 81% by closed-loop control compared with 
manual control.5 The results for FreeO2 were confirmed 
in a shorter study of 3 hours with 187 patients with acute 
hypoxemic respiratory failure due to different conditions 
in the emergency ward.6 In this study, the fraction of time 
within target SpO
2
 interval was 81% for closed-loop control 
and 52% for manual control.
Since 2011, we have worked on a closed-loop system, 
O2matic® (O2matic Ltd., Herlev, Denmark), and in this study 
we present the first data from clinical testing in a population 
admitted to hospital with an exacerbation of COPD. The aim 
of our study was to examine the ability of O2matic to keep 
SpO2 within a target interval compared to manual control 
by nursing staff and to examine if O2matic could reduce 
time with hypoxemia and time with hyperoxia compared 
to manual control. Furthermore, we wanted to evaluate the 
perception of the patients and their sense of safety in regard 
to automated oxygen control.
Methods
study design
From May to August 2018, we recruited patients at two 
pulmonary centers in Copenhagen. Twenty patients were 
recruited and entered the study in a crossover design with 
4 hours of oxygen delivery with O2matic vs 4 hours of manu-
ally controlled oxygen delivery by nursing staff. The study 
was conducted in accordance with the Declaration of Helsinki 
and was approved by The Danish Medicines Agency, The 
regional Ethics Committee (H-17040114), and the regional 
data safety board (VD-2018–44, 6248). The study was reg-
istered at ClinicalTrials.gov (NCT03464695).
equipment
The O2matic oxygen controller is a closed-loop system 
that, based on continuous monitoring of pulse and SpO
2
 
by a standard wired pulse oximeter, adjusts oxygen flow to 
the patient (Figure 1). The algorithm in O2matic samples 
the last 15 seconds of input from the pulse oximeter and 
calculates increments or decrements in oxygen flow every 
second based on the last 15 seconds’ average. Increments 
and decrements are proportionally increased relative to the 
difference between actual SpO
2
 and target SpO
2
. Maximal 
oxygen flow can be specified to fit the actual condition and 
the device used for delivering oxygen to the patient (mask or 
nasal cannula with or without humidifier). O2matic allows for 
flow up to 15 L/minute in automatic mode, but in the actual 
study most patients had a setting with acceptable flow range 
from 0 to 6 L/minute and oxygen delivered with a standard 
bore nasal cannula. If minimal SpO
2
 cannot be maintained 
with the maximal oxygen flow allowed, an alarm will sound, 
which will intensify if SpO
2
 drops .3% below target interval 
or below 85%. Alarms will also be visible and audible if 
pulse rate drops ,45 or exceeds a user-defined maximum. 
Alarm delay for loss of signal from the oximetry sensor can 
be individualized from 0 to 5 minutes, to avoid repeated 
alarms due to signal loss of shorter duration.
Patients
Patients were eligible for the study if they had a confirmed 
diagnosis of COPD and were admitted with an exacerba-
tion of COPD with an estimated length of stay .48 hours. 
Inclusion required an SpO
2
 #88% on room air. Patients 
were excluded if they had any other significant respiratory 
or cardiac condition causing hypoxemia or if they had severe 
ongoing malignancy. Patients deemed at high risk for need 
of mechanical ventilation were not included in the study. 
All patients provided written informed consent.
study intervention
Automated oxygen delivery by O2matic and manually 
controlled oxygen were delivered in random order, each 
Figure 1 The O2matic® device.
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for 4 hours with at least 16 hours between interventions 
(Figure 2). Allocation to the sequence of the two interven-
tions was done from sealed envelopes with randomized 
sequences. In automatic mode, standard SpO
2
 interval was 
set to 88%–92% and oxygen flow to 0–6 L/minute, which 
is the flow that normally can be provided with a standard 
bore nasal cannula. Both SpO
2
 interval and oxygen interval 
could be customized to individual needs. In the manually 
controlled mode, patients received oxygen from O2matic 
operating in a manual mode, so the nursing staff used the 
device as a manual-operated flowmeter. In this mode, the 
SpO
2
 and pulse rate were not visible on the screen, so they 
had to apply another pulse oximeter to read SpO
2
 and 
afterward adjust oxygen delivery. In both groups, patients 
were monitored manually at intervals defined by their Early 
Warning Score, which is a composite measure of pulse 
rate, blood pressure, SpO
2
, oxygen flow, respiratory rate, 
temperature, and level of consciousness. All events during 
the two 4 hour periods were handled by the nursing staff with 
no supervision or interventions from study investigators. 
Patients were advised to be either in bed or seated in a chair 
during the study, but they were free to remove the oximetry 
sensor during meals and visits to bathroom. Neither patients 
nor clinicians or nursing staff were blinded to the interven-
tion. Oxygen flow was delivered without humidification by 
standard nasal cannula.
study outcome
The O2matic device logs SpO
2
, pulse rate, and oxygen flow 
averaged for each 15 seconds. The primary outcome was the 
fraction of time within the target SpO
2
 interval determined 
from the log-file. Secondary outcomes were as follows:
•	 Fraction of time with severe hypoxia, defined as 
SpO
2
 ,85%
•	 Fraction of time with hypoxia, but not severe hypoxia, 
which was defined as SpO
2
 below interval, but not ,85%
•	 Fraction of time with hyperoxia, defined as SpO
2
 above 
interval.
Time without signal from the oximetry sensor was 
deducted before calculation of fraction of time within target 
or outside target. In case of hyperoxia without oxygen supply, 
this was counted as time with hyperoxia even if the device 
had no means to adjust oxygen flow to reduce hyperoxia.
Patients’ sense of comfort and security was measured 
with a not validated questionnaire with four questions:
•	 To which degree did you trust that the oximetry sensor 
stayed in place on your finger?
•	 To which degree did you trust that the device provided 
you with the right amount of oxygen?
•	 To which degree did the equipment limit your 
movements?
•	 To which degree did you feel safe regarding the oxygen 
treatment in the 4 hours where O2matic controlled the 
oxygen supply?
All questions could be answered with “Not at all”, 
“A little”, “Quite a bit”, or “Very much”.
statistical analysis
Based on an anticipated difference in fraction of time within 
target SpO
2
 interval of at least 20 percentage points and 
??????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????
?????????????? ???????????????????????????
????????????????????????????????????????????
????????????????????????????????????????????
?????????????????????????????????????
Figure 2 study design.
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a standard deviation of 28 percentage points, we needed 
15 patients to obtain a power of 80% and α of 0.05. To allow 
for dropout, we intended to include 20 patients. Data were 
tested for normality with Q–Q plots. Data that passed the 
normality test were compared with a paired t-test, whereas 
Wilcoxon signed rank test for related samples was used as a 
nonparametric test. All results were considered significant 
with P-values ,0.05. Data were analyzed with IBM SPSS 
statistical package version 22.
Results
Admitted patients at the two centers were screened for inclu-
sion and exclusion criteria upon arrival at the respiratory 
ward. Twenty-one patients fulfilled all inclusion criteria 
and none of the exclusion criteria. Only one patient did not 
want to participate; thus, 20 patients were randomized from 
May to August 2018. One patient was excluded before data 
were obtained due to wrongful inclusion. The remaining 
19 patients completed both interventions in the study. The 
baseline characteristics of the patients are shown in Table 1. 
All patients were in GOLD group D. The average number 
of serious comorbidities was 0.7. Four patients (20%) were 
at long-term oxygen treatment before the admission. Six 
patients (30%) had pneumonia at admission. At inclusion, 
the average SpO2 was 90% with average supplemental 
oxygen dosing of 1.7 L/minute. One patient had at inclu-
sion a need for 5 L/minute and acceptable flow range was 
set to 0–15 L/minute to accommodate for this. All other 
patients had lower oxygen need, and flow range was set to 
0–6 L/minute. Outcomes with deviation from the normal 
distribution were analyzed by both parametric and nonpara-
metric tests and, in all cases, let to the same interpretation 
of the results.
On average, patients received oxygen with O2matic in 
automatic mode for 267 minutes compared to 250 minutes 
in manual mode (P=0.6). Average oxygen flow rate was 
2.3 L/minute in automatic mode and 1.8 L/minute in manual 
mode (P=0.1). Average pulse rate was similar in the two 
periods (90/minute vs 88/minute, P=0.2). There was a loss 
of signal from the pulse oximeter in 2.9% of the time in auto-
mated mode and 4.5% of the time in manual mode (P=0.6). 
Loss of signal was caused either by patients not wearing the 
pulse oximeter probe during visits to bathroom, meals etc., 
or loss of signal even when the probe was in place. During 
periods with loss of signal, oxygen flow continued at the 
level used immediately before loss of signal.
Primary outcome
The O2matic device kept SpO
2
 within prespecified interval 
for 85.1% of the time vs 46.6% in manual mode, with a mean 
difference of 38.5% (CI: 27.8%–49.3%, P,0.001). The 
target SpO
2
 interval could be set individually at physician’s 
discretion. Fourteen patients had a target SpO
2
 interval of 
88%–92% whereas six patients had a specified target interval 
of 90%–94%. The fraction of time within SpO
2
 interval is 
shown in Figure 3.
secondary outcomes
Fraction of time with very low SpO
2
 (,85%) was 1.3% in 
automatic mode and 17.9% in manual mode, with a mean 
difference of 16.6% (CI: 4.0%–29.3%, P=0.01). Fraction 
of time with SpO
2
 below target but not ,85% was 9.0% 
in automatic mode and 25.0% in manual mode, with a 
mean difference of 16.0% (CI: 6.9%–25.1%, P=0.002). 
Fraction of time with high SpO
2
 above target interval was 
4.6% in automatic mode and 10.5% in manual mode, with 
a mean difference of 5.9% (CI: -3.5% to 15.3%, P=0.2). 
All results for fraction of time within different intervals are 
shown in Figure 3.
safety
In one instance audible and visible alarms for no power 
supply and low battery were ignored resulting in shutdown 
of oxygen supply after 2 hours of battery mode, which is 
in accordance with specifications for battery durability in 
O2matic. The patient was on low-dose oxygen and no harm 
was reported, but equipment alarms were afterward adjusted 
to flash on the screen if there is a lack of power supply and 
warn that there could be imminent shutdown. No other safety 
issues were observed.
Other outcomes
Out of the 19 patients completing the study, 13 completed 
an interviewer-administered questionnaire about how they 
felt regarding the automated oxygen treatment with O2matic. 
Table 1 Patient characteristics
Characteristics Mean±SD or number (%)
age (years) 72.4±8.4
Women/Men 12 (60)/8 (40)
FeV1 (l) 0.72±0.31
FeV1 (% predicted) 33±17
FeV1/FVC 0.46±0.10
gOlD group 1/2/3/4 0 (0)/4 (20)/6 (30)/10 (50)
Body mass index (kg/m2) 25.2±7.1
smokers/ex-smokers/nonsmokers 5 (25)/15 (75)/0 (0)
Pack years 41±14
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Missing data on six subjects was due to lack of follow-up 
when study was completed as there was no investigator avail-
able to administer the questionnaire. Eight (62%) expressed 
very high confidence in getting the right amount of oxygen, 
four (31%) expressed quite a bit confidence, and one (8%) 
did not know. None expressed little or no confidence. Limi-
tation of movements due to the wired pulse oximeter was 
an issue. Three (23%) felt very much limited, six (46%) felt 
a little limited, three (23%) felt no limitation, and one did 
not answer. Eleven (85%) felt very safe regarding the risk 
of misplacing the pulse oximeter probe during rest and two 
(15%) felt quite a bit safe. None felt only a little or not safe. 
Overall, sense of safety with the concept of automated oxygen 
delivery was very high. Twelve (92%) expressed that they 
felt very safe, and one (8%) felt quite a bit safe. None felt 
only a little or not safe.
Discussion
This study reports the first clinical data on closed-loop control 
of oxygen supply with O2matic to patients admitted with an 
exacerbation of COPD. The data show that automated oxygen 
supply is feasible and superior to manual control by nursing 
staff in maintaining SpO
2
 within the prescribed interval. 
Especially, episodes with very low SpO
2
 (,85%) and low 
SpO
2
 (below target but not ,85%) were significantly reduced 
with O2matic compared with manual control, whereas epi-
sodes with high SpO2 (above target interval) showed a trend 
to reduction from 10.5% to 4.6%. These results are well in 
line with previous studies on closed-loop oxygen control. 
The FreeO2 device from Canadian company OxyNov has 
shown similar figures for time within prescribed interval for 
patients with COPD and for patients with acute hypoxemia in 
the emergency ward.5,6 However, the figures are not necessar-
ily comparable, as our study was a daytime crossover study 
in a pulmonary ward, whereas the studies with FreeO2 were 
with a parallel design and either of longer duration includ-
ing nighttime or in an emergency room setting. Closed-loop 
control of oxygenation has also been shown to be feasible 
in other settings such as neonates, during exercise, and in a 
home setting.7–13
We were not able to demonstrate a reduction in oxygen 
consumption with O2matic compared to manual control. 
Average flow rate was 2.3 L/minute with O2matic and 
1.8 L/minute with manual control, which was not sig-
nificantly different. However, out study was not powered to 
study this outcome. In the two studies of FreeO2, there was 
a tendency toward a reduction in oxygen consumption in 
one study from 1.2 L/minute to 0.7 L/minute (P=0.06), and 
no overall difference in another study where average flow 
rate was 4.6 L/minute with FreeO2 and 4.2 L/minute with 
manual control.5,6 The tendency in our study toward lower 
flow rate with manual control than with O2matic is consistent 
with the patients being hypoxemic in a large proportion of 
the time with manual control. Thus, actual oxygen flow rates 
with manual control were often inadequate to maintain the 
prescribed SpO
2
.
???
?????? ??????? ?????
?????????????????????????? ???????? ??????????????? ?????????????? ???????????
????????????????
?? ?????????????
Figure 3 Fraction of time with different levels of spO2 for O2matic
® (blue bars) and manual control (red bars).
Abbreviation: spO2, oxygen saturation.
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It is well documented that prescription practices for 
oxygen supplementation and adherence to prescriptions are 
very poor, probably reflecting unawareness about the neces-
sity of accurate oxygen prescription and therapy.14 An audit in 
2013 by the British Thoracic Society found that only 55% of 
patients who were administered oxygen during an admission 
had a written prescription.15 However, this was an improve-
ment from 2008, where only 32% of patients supplied with 
oxygen had a written prescription. In an Australian audit, 
only 3% of in-patients with an exacerbation of COPD had 
a written oxygen prescription despite 79% of the patients 
receiving oxygen supplementation.16 In a large European 
audit in 2010–2011 of 16,018 patients with an exacerbation 
in COPD, it was found that 10.1% received inappropriate 
oxygen therapy, either with high flow oxygen or no oxygen 
despite being hypoxic.17
Patients’ acceptance of automated oxygen delivery in our 
study was very high, and in general, the patients expressed 
very high confidence in the concept and felt secure that they 
received the right amount of oxygen. However, limitation of 
movements due to the wired pulse oximeter was an issue for 
some patients. As our study was limited to two times 4 hours 
of continuous SpO
2
 monitoring during daytime, longer studies 
including nighttime are needed to properly evaluate patient 
experience with continuous monitoring and oxygen control.
Our study was a crossover study and thus did not allow for 
examining outcomes such as time for weaning from oxygen 
and duration of admission. Other studies have shown that 
closed-loop control of oxygen probably allows for faster 
weaning from oxygen and shorter admission time and thus 
could be very cost-effective compared with manual control 
by nursing staff.5,6 We found that the crossover design was 
ideal as no carryover effect was to be expected in relation to 
the treatment outcome which was SpO
2
 in response to oxygen 
treatment. Still we used a washout period of 16 hours, 
primarily to secure that O
2
 titration in the active arm did not 
influence the dosing of O
2
 in the manual arm. Furthermore, 
to evaluate if there was a systematic change in the condition 
from day 1 to day 2 of the intervention, we examined for a 
period effect with oxygen flow and SpO
2
 within target inter-
val on day 1 and day 2 and found no significant differences 
in those two parameters.
It was not possible to blind our study, as the nursing 
staff had to manually adjust oxygen in the control arm. 
This difference was also visible to the patients due to the 
manual adjustments in one arm, and due to difference in 
O2matic user screen setup, where pulse rate and SpO
2
 were 
not visible in the control arm and the O2matic was used as 
a manual flowmeter. However, as our main outcome was a 
physiological parameter (SpO
2
), the lack of blinding is not 
considered to have influenced the results regarding SpO2 
data, but it could possibly confound the questionnaire data. 
Time outside target saturation interval for manual control 
was comparable with results from other studies.5,6
A relevant issue is the clinical importance of maintain-
ing SpO
2
 within a rather narrow interval. There is a lack of 
controlled studies of the outcome in clinical terms of pre-
scribing and adhering to different oxygen dosing regimes 
for patients with an exacerbation of COPD, but a low as 
well as a high SpO
2
 on admission has been associated with 
worse outcome in terms of mortality or other serious adverse 
outcome.3,4 It seems reasonable to assume that the findings 
from studies at prehospital level and on admission to some 
extent can be extrapolated to similar conditions during an 
admission, but further studies are needed to evaluate clini-
cal outcomes related to episodes with prolonged hypoxemia 
and hyperoxia. We did not evaluate the effect of closed-loop 
control of oxygen on arterial CO
2
 tension (PaCO
2
) in our 
study. An increase in arterial oxygen tension is known to 
increase PaCO
2
 due to the Haldane effect and due to increased 
dead-space ventilation, caused by reversal of hypoxemic 
pulmonary vasoconstriction and worsening in ventilation-
perfusion mismatch.18 However, the recommended strategy 
for avoiding CO
2
 retention is to eliminate hyperoxia and 
control SpO
2
 in the interval 88%–92%.2 This makes CO
2
 
retention more unlikely when SpO
2
 is better controlled, as 
is the case in our study with O2matic.
Conclusion
We found that O2matic was able to effectively control SpO
2
 
for patients admitted with an exacerbation of COPD. O2matic 
was significantly better than manual control by nursing staff 
to maintain SpO
2
 within the specified interval and to reduce 
time with unintended hypoxemia. The patients accepted 
automated oxygen control without reservations and felt safe 
about getting the right amount of oxygen. Whether such a 
strategy for oxygen therapy during admission can reduce 
admission length, and possibly improve survival among 
COPD patients, remains to be determined.
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